Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Larysa, Wang, Yucai, Siegel, David S., Wang, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929758/
https://www.ncbi.nlm.nih.gov/pubmed/27363983
http://dx.doi.org/10.1186/s13045-016-0283-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929758/
https://www.ncbi.nlm.nih.gov/pubmed/27363983
http://dx.doi.org/10.1186/s13045-016-0283-0

Ejemplares similares